Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol, this public meeting killed it hahhahaha
does somebody know at which time the public meeting will be held tomorrow?
So you mean there will be concerns, which must be cleared out first? And that takes time?
Am I right, that we will know in 2 trading day, if there are concerns from the public?
Hi walterc,
do you know if he will visit Frankfurt am Main in DE?
Would like to meet him in person.
Thanks a lot photo
Agree, it's just curious why to sell now and if he know something, why sell shares for 5k$, that is peanuts for him.
Why has Morabito, Mark Joseph sold shares on the 6th of february for 5k$?
If you also look for an excelent opportunity -> EXMGF
Do your DD and invest, 27.02.2018 will be the day of public meeting to finish final approval.
I used the pump to dump my shares.
Still to long to wait and i guess they will need money in near future.
Will be back in half a year.
Stealth godmode = on
Agree, we are even lower than that.
Its just we lose good momentum and have to wait longer.
I'll definitely buy some more in the next weeks at 1.00 CAD ;)
1.00 CAD here we go
Ok, I'll get my bonus from my company at mai, so I will buy some more at this time.
I guess it will stay low or get even lower due to more time to wait.
At least till beginning of march?
How many day following the public meeting on FEBRUARY 27, 2018 is needed to get a final permit?
Why should they extend the period if all is good and nobody is complaining?
Is that preliminary permit enough to start contruction?
New week, no news?
lol 5th patient has been treaded on 11th of january.
4 patients still pending. Loooooooong time to go.
Theralase Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 11, 2017, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology.
The anti-cancer PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours. The bladder is then drained of the solution, flushed with sterile water to remove non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, known as a Dosimetry Fibre Optic Cage (“DFOC”) with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the absorbed PDC, for the intended destruction of the NMIBC tumours.
The Study is being used to evaluate TLD-1433 for the primary endpoint of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.
Three patients have been enrolled and treated at the Maximum Recommended Starting Dose (0.35 mg/cm2). Two patients have been enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with an additional four patients remaining to be enrolled and treated at the Therapeutic Dose to complete the Study.
If Health Canada regulatory approval of the Study is achieved, subject to Health Canada and FDA regulatory approval, the Company plans to commence a multi-center Phase II NMIBC clinical study, with a primary endpoint of efficacy.
Theralase Optimizes Delivery Schedule of Anti-Cancer Vaccine in Destruction of Brain Cancer
Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a biotech company focused on the commercialization of medical lasers to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer has announced an optimization to the delivery schedule of its proprietary anti-cancer vaccine, increasing its efficacy in the destruction of brain cancer.
The anti-cancer vaccine was evaluated in a rat glioma (“RG2”) animal model, an established model of Glioblastoma Multiforme (“GBM”), a deadly form of human brain cancer.
As originally disclosed, the anti-cancer vaccine was created by exposing RG2 cells to patented stressors extracorporeally (outside the body) and then injecting this anti-cancer vaccine into rats to delay the progression of brain glioma tumours.
The previous data obtained in this model demonstrated an increase of 35% in the survival of animals that have been vaccinated twice versus control (non-vaccinated rats).
To view the graphic in its original size, please click here
In the latest research, rats were vaccinated twice and then subjected to glioma (brain tumour) induction. Post brain tumour induction, as an optimization, four additional maintenance vaccinations were completed.
The latest data obtained on the optimized delivery timetable (six vaccinations versus two vaccinations) demonstrated a material increase in the survival of animals from 35% to 87.5%.
To view the graphic in its original size, please click here
In order to transfer this research from the lab (animals) to the clinic (humans), potentially helping the patients in most need of the treatment, Theralase is in the process of developing two separate clinical treatment paths for patients diagnosed with GBM, with the aim of safely and effectively destroying their cancers with minimal side effects.
It is expected that the first Phase Ib GBM clinical study would generally involve the patient:
1) receiving primary treatment, such as: surgical debridement, temozolomide (oral chemotherapy drug) and / or radiation therapy
2) receiving the Theralase anti-cancer vaccine (created from the patient’s own tumour cells), post primary treatment, via subcutaneous or intramuscular injections, to stimulate the body’s immune system to destroy residual GBM cancer cells.
It is expected that the second Phase Ib GBM clinical study would generally involve the patient:
1) receiving an intravenous injection of Rutherrin®, a patented PDC (TLD-1433) drug formulation combined with transferrin
2) having the drug activated by laser light (via surgically inserted optical fibers) and/or ionizing radiation (using conventional trans-cranial (non-invasive) X-ray treatment), at 8 to 24 hours post-injection (allowing Rutherrin® to cross the blood brain barrier and be selectively absorbed into the GBM cancer cells).
3) receiving additional PDT and/or radiation treatments (Step 1 and 2) to destroy any residual tumours, as required.
4) receiving the Theralase anti-cancer vaccine (created from the patient’s own tumour cells), post treatment, via subcutaneous or intramuscular injections, to stimulate the body’s immune system to destroy residual GBM cancer cells.
There are an estimated 24,000 new cases of malignant gliomas diagnosed in the US annually, with more than 14,000 deaths.
In the majority of cases, they recur following initial treatment, especially for GBM, the most common and lethal form of brain cancer.
Most patients do not survive beyond 2 years, post diagnosis.
Next steps planned by the Company to develop this technology are expected to include: manufacturing and scale-up of the anti-cancer personalized vaccine, regulatory approval to use an anti-cancer vaccine in human application, the recruitment of neurological oncology specialists to the Theralase Medical and Scientific Advisory Board and with their assistance the design and commencement of a Phase Ib GBM clinical study.
Manjunatha Ankathatti Munegowda, Ph.D., DVM, Research Scientist, Theralase, stated that, “In previous research, we demonstrated that the newly developed anti-cancer vaccine increased survival in an aggressive brain cancer model by 35%. Optimization of the delivery timetable, by repeatedly stimulating the immune response with multiple vaccinations, has increased survival by 87.5%. This anti-cancer vaccine could be used to target and eliminate any recurrences, post primary treatment, by delivering vaccinations to the patient from a stored bank of their own patient specific anti-cancer vaccines.”
Arkady Mandel M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase stated, “Theralase has designed and put into development a specific autologous (prepared from the patient’s own cancer cells) anti-cancer vaccine. In the latest research, utilizing the RG2 cell line as a model of human GBM, Theralase has demonstrated that its anti-cancer vaccine is effective. The anti-cancer vaccine is personalized and designed to train the patient’s immune system to develop a specific immune response creating anti-cancer immune cells that remember, hunt, recognize and kill a patient’s brain cancer cells regardless of where they may be located in the body.”
Dr. Mandel went on to say, “The latest optimized results confirm the efficacy of the vaccine via multiple vaccinations. The anti-cancer vaccine is non-toxic and has no noticeable adverse effects, when tested in an established animal model. Theralase is currently investigating the GMP scale-up of the anti-cancer vaccine with a cell based drug manufacturer to produce patient specific anti-cancer vaccines and maintain their ongoing storage, preservation and delivery to patients, as required. This latest research supports Theralase’s belief that teaching the immune system to destroy cancer cells throughout the body is one of the keys to conquering cancer.”
Potential risks to the development and commercialization of this technology include:
1) Successful transfer of the anti-cancer vaccine technology from lab (animals) to clinic (humans)
2) Successful manufacture and scale-up of the anti-cancer vaccine
3) Sufficient capitalization to execute human clinical trials
4) Health Canada and FDA regulatory approval to commence human clinical trials
5) Successful regulatory approval of the human clinical trials upon completion
6) Demonstrated safety and efficacy benefits over current standard of care treatments
it lasts long to close 2nd trance
and no info on permit.
comon!
Hi Lubins,
it seems you are new to niocorp.
Its already known, that niocorp usually misses its targets.
You need to be relaxed and stress-resistant.
I guess its a good number of thumb to expect all twice as long.
Dont get me wrong. As I already wrote, I'm back in since december and just waiting.
Good volume today
Somebody knows something? hmmm
I guess it will change right before official open
Well, I see ;)
So you mean high probability for a trading hold for further permit information?
Early tsx premarket 1,27 CAD bid and ask
Next boost just started.
Will we break 1,3 CAD again?
Good to see him and 100% increase in share price, but it seems to take some more month for financing news.
Thought they have said something about end of 2017 or january 2018 due to holiday season.
Lot going on but that will take time to evaluate every possibility.
I'm just saying.
Landed on upper flag line.
Kick it to orbit now
Thanks for the links, havent seen it yet.
Does somebody know when they are running out of money?
hi trofee, no I'm german and no, 88 is my year of birth ;)
IBC and NioCorp Announce Successful Completion of Initial Casting Campaign for Aluminum-Scandium Alloys
Wilmington, MA (December 28, 2017) -- IBC Advanced Alloys (TSX-V: IB; OTCQB: IAALF) (“IBC”) and NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF, FSE: BR3) (“NioCorp”) (collectively the “Companies”) today announced the successful manufacture of several aluminum-scandium alloy ingots. These test pours occurred at IBC’s Wilmington, Massachusetts Engineered Materials facility using scandium purchased commercially by NioCorp.
Video of IBC's Aluminum-Scandium Alloy Pour
Video of Aluminum-Scandium Alloy Pour
IBC Produced Aluminum-Scandium Alloy
The ingots, representing a range of scandium content, will now undergo chemical analysis and other metallurgical testing to confirm the microstructure and performance of the alloys. This testing is the basis for commercializing Aluminum-Scandium alloys.
“I am very pleased with the successful execution by Chris Huskamp and his team of this initial production campaign, and we look forward to reviewing the results of follow-on testing to confirm material specifications,” said Major General Duncan (“David”) Heinz (USMC, ret.), IBC’s President and CEO. “This is a significant milestone in our joint development effort with NioCorp to seed the market in order to unlock the enormous value of scandium in a wide range of high-performance applications across multiple markets.”
“This is an exciting launch of what could be a new phase of commercial operations for both IBC and for NioCorp,” said Mark A. Smith, who serves as Chair of IBC’s Board and is Executive Chair and CEO of NioCorp. “Developing high-performance alloys and processes that incorporate metals such as scandium requires significant expertise and know-how. The Board and I look forward to Chris’ team continuing to advance this effort toward a potential launch of new commercial operations.”
Alloys that incorporate scandium have been produced for more than 50 years for a wide variety of applications in the defense and civilian sectors. When combined with aluminum and other metals, for example, scandium helps to make a very strong and lightweight alloy material that can deliver significant performance enhancements, weight savings, fuel efficiency, and air emissions reductions in transportation systems. The former Soviet Union reportedly used scandium-bearing alloys in high-performance jet fighters and in other military aerospace systems.
However, despite the many well-understood benefits of scandium, widespread use of the metal has been limited by severely constrained global supply chains. No single dedicated mine in the world today currently produces scandium, and only 10-15 tonnes of scandium oxide material is estimated to be produced globally. OnG Commodities LLC has estimated latent demand for scandium at several hundred tonnes per year in the aerospace sector alone.1
Supply-Demand Forecast for Scandium Oxide to 2028, Tonnes, Base Case1
Source: OnG Commodities LLC
Mr. Huskamp, who leads IBC’s team of metallurgists and alloy production specialists, is President of IBC’s Engineered Materials Division, which currently manufactures high-performance beryllium-aluminum alloy parts for a number of systems in both the defense and civilian sectors. Mr. Huskamp is a former Boeing Associate Technical Fellow in advanced metallic processes, and is credited as a named co-inventor of two patents regarding scandium-bearing aluminum alloys.
NioCorp is currently developing the Elk Creek Superalloy Materials Project, an advanced materials processing facility planned for southeast Nebraska that expects to produce just over 100 tonnes per year of scandium trioxide, as well as niobium and titanium products. Such large-scale production of scandium in Nebraska would establish the United States as a global superpower of scandium.
For more information on IBC and its innovative alloy products, go here.
PP closes today?
You made my day, same thought here
Nice, thanks Photo
Still no scandium test results
Hi walterc,
do you know when to expect next milestone or news release?
Have there been an information about news in near future?
Thanks,
Yes, I agree.
But why is there not a 2/3 debt and 1/3 equity financing package?